Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017 08; 18(8):1089-1103.

View in: PubMed

subject areas

Aged
Antibiotics, Antineoplastic
Antineoplastic Combined Chemotherapy Protocols
Disease-Free Survival
Doxorubicin
Drug Eruptions
Exanthema
Female
Hematologic Diseases
Humans
Male
Middle Aged
Nitroimidazoles
Phosphoramide Mustards
Sarcoma
Soft Tissue Neoplasms
Stomatitis
Survival Rate

authors with profiles

Robin Jones